Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Archivos del Instituto de Cardiologia de Mexico

[Hypoalphalipoproteinemia and atherosclerosis. Genetic and biochemical profile of 10 families].

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Povezava se shrani v odložišče
M Ahumada Ayala
C Jiménez Villanueva
G Cardoso Saldaña
J C Sienra Pérez
J Zamora González
C Posadas Romero

Ključne besede

Povzetek

The results of lipoprotein studies performed in 67 members of 10 kindreds with familial hypoalphalipoproteinemia are presented. Probands were ten patients referred to the Lipid Clinic of the National Institute of Cardiology for evaluation of their lipid profile, all of whom had history of a definite myocardial infarction occurring before they had reached age 60. Their only plasma lipid abnormality was a reduction of the cholesterol fraction associated with high-density lipoproteins (C-HDL) below the corresponding age-sex specific fifth percentile. We studied 57 other individuals including probands spouses and available first-degree relatives. All participants were clinically examined and their complete coronary risk factor profile was assessed. After a 12 hour fast, plasma samples were obtained for lipid analysis, total cholesterol and trïglycerides were measured by enzymatic methods, C-HDL was determined in the supernatant after plasma precipitation with magnesium chloride: phosphotungstic acid. Low-density lipoprotein cholesterol (C-LDL) was estimated with the formula proposed by DeLong. For every family a pedigree was constructed and statistically analyzed to assess the within-family clustering of low C-HDL levels and the pattern of transmission of the abnormal phenotypes. Mean C-HDL level for propositii was 24.3 mg/dl, the corresponding value for the C-LDL/C-HDL ratio (atherogenic index) was 4.9 and it was elevated above 3.5 (average coronary risk) in 7/10 (70%) of these patients. Obesity, defined by a Quetelet index above 28 in men and 26 in women was present in 4/10 (40%) of the probands, 3/10 (30%) had stable non insulin-dependent diabetes mellitus, prevalence figures for the other coronary risk factors was very low. In addition to probands, the hypoalphalipoproteinemic phenotype was found in 30/57 (52.6%) subjects including spouses (two cases) and first-degree relatives. For these 30 cases the mean C-HDL value was 32 mg/dl. In all ten reported kindred, we clearly observed either horizontal, vertical or both types of within-family transmission of the aberrant phenotype. This finding was considered to be most compatible with the presence of a primary genetic abnormality affecting C-HDL metabolism in all these kindreds in spite of the fact that some of the probands had some conditions like diabetes or obesity that are sometimes associated with secondary reductions of C-HDL. Due to the lack of a reliable biochemical marker, the distinction between primary and secondary hypoalphalipoproteinemia in individual cases is frequently impossible, for this reason the diagnostic assessment depends on family studies.(ABSTRACT TRUNCATED AT 400 WORDS)

Pridružite se naši
facebook strani

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

  • Deluje v 55 jezikih
  • Zeliščna zdravila, podprta z znanostjo
  • Prepoznavanje zelišč po sliki
  • Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
  • Preberite znanstvene publikacije, povezane z vašim iskanjem
  • Iščite zdravilna zelišča po njihovih učinkih
  • Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah

Google Play badgeApp Store badge